Results 181 to 190 of about 72,405 (280)

Randomised treatment of acute pancreatitis with infliximab: protocol for a double-blind, placebo-controlled, multi-centre, adaptive, phase 2 superiority trial (RAPID-I). [PDF]

open access: yesBMJ Open
Lin J   +30 more
europepmc   +1 more source

Pathogen‐Specific Bloodstream Infections Associated With Tumour Necrosis Factor‐α Inhibitors, Vedolizumab and Ustekinumab in Inflammatory Bowel Disease: A Danish Nationwide Case‐Control Study 2010–2024

open access: yesAlimentary Pharmacology &Therapeutics, Volume 64, Issue 11-12, Page 1597-1606, December 2026.
In this nationwide study of patients with inflammatory bowel disease, TNF inhibitor use was associated with higher bloodstream infection rates, whereas vedolizumab and ustekinumab was not. Associations differed by pathogen species, and concomitant glucocorticoid use was associated with higher infection rates.
Cæcilie Leding   +4 more
wiley   +1 more source

Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritis

open access: yes
Objective: to describe real world experience of switching from originator TNF inhibitor Remicade (infliximab), to the biosimilar Inflectra (infliximab) in severe inflammatory arthritis. Methods: from May 2015 patients receiving Remicade (infliximab) were
Underhill, C.   +10 more
core  

Meta‐Analysis: Safety and Effectiveness of Advanced Therapies in Inflammatory Bowel Disease Patients With Concomitant Primary Sclerosing Cholangitis

open access: yesAlimentary Pharmacology &Therapeutics, Volume 64, Issue 11-12, Page 1500-1519, December 2026.
Advanced IBD therapies appear safe and effective in PSC‐IBD. However remission and response rates appear numerically attenuated compared to IBD‐only populations. Created in BioRender (https://BioRender.com/h9bxgij). ABSTRACT Background Inflammatory bowel disease (IBD) associated with primary sclerosing cholangitis (PSC) is a distinct phenotype (PSC‐IBD)
Amera Elzubeir   +6 more
wiley   +1 more source

Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study

open access: yesInternational Journal of Dermatology, Volume 65, Issue 12, Page 2524-2531, December 2026.
This multicentre real‐world study illustrates the heterogeneity of systemic treatment approaches in erythrodermic psoriasis (EP) in Bavaria, Germany. Adverse events were more frequently observed with conventional therapies, whereas biologic therapies showed favorable outcomes.
Julian Kögel   +15 more
wiley   +1 more source

Autologous hinge-masked anti-TNFα antibody to mitigate immunogenicity, antigen sink effects, and anti-idiotypic antibody interference. [PDF]

open access: yesJ Biol Eng
Huang BC   +12 more
europepmc   +1 more source

Emerging Roles of PSTPIP2 in Autoimmunity: From Mechanism to Therapeutic Implications

open access: yesImmunology, Volume 179, Issue 4, Page 565-578, December 2026.
PSTPIP2 acts as a key brake on myeloid inflammation by suppressing IL‐1β‐driven signalling, macrophage dysregulation and inflammation‐associated bone remodelling. Its emerging roles in CRMO/CMO, rheumatoid arthritis, SAPHO syndrome and bullous pemphigoid support its potential as a biomarker and therapeutic target.
Erdong Zhang   +9 more
wiley   +1 more source

Associations of Rheumatoid Arthritis Disease Activity With Frailty Over Five Years of Follow‐up

open access: yesArthritis Care &Research, Volume 78, Issue 11, Page 1759-1768, November 2026.
Objective To evaluate whether rheumatoid arthritis (RA) disease activity is associated with frailty both in cross‐section and longitudinally. Methods Participants within the Veterans Affairs Rheumatoid Arthritis (VARA) registry enrolled from 2003 to 2022 were included.
Courtney N. Loecker   +14 more
wiley   +1 more source

Real-World Experience of Risankizumab in Refractory Pediatric Inflammatory Bowel Disease. [PDF]

open access: yesACG Case Rep J
Alsarhan A   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy